Literature DB >> 14523773

Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics.

Tariq A Madani1, Yagob Y Al-Mazrou, Mohammad H Al-Jeffri, Amin A Mishkhas, Abdullah M Al-Rabeah, Adel M Turkistani, Mohammad O Al-Sayed, Abdullah A Abodahish, Ali S Khan, Thomas G Ksiazek, Osama Shobokshi.   

Abstract

This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).

Entities:  

Mesh:

Year:  2003        PMID: 14523773     DOI: 10.1086/378747

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  185 in total

1.  Rift Valley Fever: scientific pathways toward public health prevention and response.

Authors:  Robert F Breiman; Bruno Minjauw; S K Sharif; Peter Ithondeka; M Kariuki Njenga
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

2.  Risk assessment of the introduction of Rift Valley fever from the Horn of Africa to Yemen via legal trade of small ruminants.

Authors:  Shaif Abdo-Salem; Agnès Waret-Szkuta; François Roger; Marie-Marie Olive; Khalid Saeed; Véronique Chevalier
Journal:  Trop Anim Health Prod       Date:  2010-10-22       Impact factor: 1.559

3.  Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats.

Authors:  Aaron W Walters; Michael R Kujawa; Joseph R Albe; Douglas S Reed; William B Klimstra; Amy L Hartman
Journal:  Virology       Date:  2018-11-02       Impact factor: 3.616

Review 4.  The ecology of emerging neurotropic viruses.

Authors:  Kevin J Olival; Peter Daszak
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

Review 5.  Emerging infectious diseases: the Bunyaviridae.

Authors:  Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

6.  Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry.

Authors:  Brian H Bird; Marina L Khristova; Pierre E Rollin; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

7.  Development and evaluation of a real-time reverse transcription-loop-mediated isothermal amplification assay for rapid detection of Rift Valley fever virus in clinical specimens.

Authors:  C A Le Roux; T Kubo; A A Grobbelaar; P Jansen van Vuren; J Weyer; L H Nel; R Swanepoel; K Morita; J T Paweska
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

8.  Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases.

Authors:  M Kariuki Njenga; Janusz Paweska; Rose Wanjala; Carol Y Rao; Matthew Weiner; Victor Omballa; Elizabeth T Luman; David Mutonga; Shanaaz Sharif; Marcus Panning; Christian Drosten; Daniel R Feikin; Robert F Breiman
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

9.  The first serological evidence for Rift Valley fever infection in the camel, goitered gazelle and Anatolian water buffaloes in Turkey.

Authors:  Sibel Gür; Mehmet Kale; Nural Erol; Orhan Yapici; Nuri Mamak; Sibel Yavru
Journal:  Trop Anim Health Prod       Date:  2017-08-31       Impact factor: 1.559

10.  Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife.

Authors:  A Evans; F Gakuya; J T Paweska; M Rostal; L Akoolo; P J Van Vuren; T Manyibe; J M Macharia; T G Ksiazek; D R Feikin; R F Breiman; M Kariuki Njenga
Journal:  Epidemiol Infect       Date:  2007-11-08       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.